Using data from the University of Wisconsin Transdisciplinary Tobacco Use Research Center (UW-TTURC), we have previously shown that CHRNA5 gene modulates clinical response to NRT. Specifically, smokers with the high risk genotypes were less likely to quit while receiving placebo medication (Chen et al., 2012). Whether the effects of these two effective pharmacotherapies (cNRT and varenicline) vary with CHRNA5 is of clinical interest because these results may potentially inform medication choice.
